For more than ten years, TNI’s Drugs & Democracy programme has been studying the UN drug control conventions and the institutional architecture of the UN drug control regime. As we approach the 2016 UNGASS, this primer is a tool to better understand the role of these conventions, the scope and limits of their flexibility, the mandates they established for the CND, the INCB and the WHO, and the various options for treaty reform.
Preparations are gathering pace for the United Nations General Assembly Special Session (UNGASS) on drugs, to be held on the 19th to 21st April 2016 in New York. Following several months of discussion on procedural elements, attention is now focused on negotiating the content of the "short, substantive, concise and action-orientated outcome document comprising a set of operational recommendations" to be approved by the General Assembly next April. At the CND intersessional meeting on 12th June, countries and regional groups were invited to submit their first ideas for what could be included in this Outcome Document, by a deadline of 11th September.
On 19th to 21st April 2016, there will be a United Nations General Assembly Special Session (UNGASS) held in New York, dedicated to the issue of drug policy. The General Assembly is the highest policy making and representative organ of the United Nations (UN), and its infrequent Special Sessions focus on pertinent topics at the request of member states. The UNGASS on drugs has the potential to be a ground-breaking, open debate about the international drug control system – but there is much work to be done to ensure that it fulfils that potential.
Just over one year away from the 2016 UNGASS, denying the reality that the drug policy landscape has fundamentally changed and that tensions with the UN drug conventions are occuring, is no longer a credible option. Secretary General Ban Ki-moon urged member states to use the 2016 UNGASS on drugs "to conduct a wide-ranging and open debate that considers all options." TNI calls for a special advisory group that should be tasked with recommending how to better deal with the contentious issues following the 2016 UNGASS, in preparation for the next UN high-level review in 2019.
Since 1909 the international community has worked to eradicate the abuse of narcotics. A century on, the efforts are widely acknowledged to have failed, and worse, have spurred black market violence and human rights abuses. How did this drug control system arise, why has it proven so durable in the face of failure, and is there hope for reform?
Peter Reuter (RAND), Franz Trautmann (Trimbos Institute) (eds.)
15 မတ်လ 2009
This report commissioned by the European Commission, found no evidence that the global drug problem has been reduced during the period from 1998 to 2007 – the primary target of the 1998 UNGASS, which aimed to significantly reduce the global illicit drugs problem by 2008 through international cooperation and measures in the field of drug supply and drug demand reduction. Broadly speaking the situation has improved a little in some of the richer countries, while for others it worsened, and for some of those it worsened sharply and substantially', among which are a few large developing or transitional countries. Given the limitations of the data, a fair judgment is that the problem became somewhat more severe.
The Executive Director of UNAIDS, Michel Sidibé, wrote a letter to the delegates negotiating the Political Declaration for the 52nd session of the UN Commission on Narcotic Drugs (CND) in Vienna on March 11-12, 2009, dedicated to review of the progress achieved and the difficulties encountered by in meeting the goals and targets set out in the 1998 UNGASS.
A useful overview of UN endorsement of harm reduction measures; the legality of harm reduction services under the Drug Conventions; the obligation in human rights law to ensure access to harm reduction services and the global state of harm reduction, listing 82 countries and territories worldwide that presently support or tolerate harm reduction.
The review of the objectives and action plans agreed at the 1998 UNGASS on Drugs has reached a critical stage. Following the thematic debate at the 2008 Commission on Narcotic Drugs, and the five expert working groups held in Vienna over the summer, the attention now moves to the political process of negotiating the text of a political declaration to be agreed at the high level meeting in March 2009.
On October 2, 2008, the Beckley Foundation launched in the House of Lords its Global Cannabis Commission Report, an authoritative guide to the effects of cannabis, the policies that control its use, and recommendations for policy reform. A team of leading drug policy analysts prepared an overview of the latest scientific evidence surrounding cannabis and the policies that control its use.
The "Beyond 2008" NGO Forum was held in Vienna, Austria from July 7-9, 2008. It was the final step in the global consultation of NGOs involved in responding to drug related problems and to provide civil society input for the 10-year UNGASS review.
Three draft resolutions and the draft declaration were subject to a line by line examination and intense debate. At the end of the Forum the Declaration and three Resolutions were adopted by consensus by all those participating in the Forum. This was an historic achievement and reflected the maturity and commitment of the global NGO community.
Martin Jelsma, from the Transnational Institute, prepared an analysis for theLatin American Commission on Drugs and Democracy, explaining the drug policy situation in the European Union and the current state of debate in the United Nations agenda. The commission is an initiative born of former presidents Fernando Henrique Cardoso, from Brazil, César Gaviria, from Colombia and Ernesto Zedillo, from Mexico, to respond to concerns related to the problems of drug consumption and traffic in Latin America. The idea to constitute a commission capable of consolidating a debate concerning this problematic also responds to the necessity of reviewing the world drug policies in the scope of the United Nations, which began in March 2008.
Weaknesses in the United Nations drug control system have often been identified, related to the functioning of the key organs – the UN Office on Drugs and Crime (UNODC), International Narcotics Control Board (INCB), and the Commission on Narcotic Drugs (CND) –, related to collaboration with the wider UN system – the World Health Organistaion (WHO), UNAIDS, UN Development Programme (UNDP), etc. – and related to the outdated character of several treaty provisions.
On thursday 28 February 2008 the Dutch Parliamentary Justice Commission devoted its debate to the drugs UNGASS review. Martin Jelsma was invited as one of the experts to share with the commission TNI's views on the importance of the review process. In his contribution he highlights the opportunity to use the 2008/9 period to achieve a breakthrough on harm reduction acceptance at the UN level, to evaluate the performance of UN agencies like UNODC and the INCB, and to open the door for a revision of the UN drug control treaty system. only available in Dutch
TNI co-signed a letter that was sent to the Dutch Prime Minister and relevant parliamentary commissions, stressing the need for an active Dutch involvement in the UNGASS review process and specifically to use the moment to open the discussion about the UN conventions that are an obstacle to further developments in Dutch cannabis policy.
Meetings of the Commission on Narcotic Drugs (CND) are no forum for debate and change. The author, a former senior officer of the United Nations International Drug Control Programme (UNDCP), shows how CND meetings are manipulated in the interests of 17 developed countries that largely fund UNDCP – the CND’s ‘civil service’. However, these major donors are not united on policy or on how to apply the UN drug Conventions, so CND decisions reflect the lowest level of disagreement, with major splits on policy ignored.